A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

Acute Myeloid Leukemia Clinical Trial

Official title:

A Randomized, Open-label, Two-period, Two-way Crossover Bioequivalence Study of Two (Cytarabine: Daunorubicin) Liposome for Injection in Elderly AML Subjects

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05801835
• Other study ID #: HC1702-003
• Status: Recruiting
• Phase: N/A
• Start date: August 25, 2023
• Est. completion date: December 2025

Study information

• Verified date: September 2023
• Source: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
• Contact: Jianxiang Wang, MD
• Phone: 86-022-23909120
• Email: wangjx[@]ihcams.an.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the bioequivalence of (cytarabine: daunorubicin) liposome for injection and Vyxeos in elderly acute myeloid leukemia (AML) subjects.

Description:

This is a multi-center, randomized, open-label, two-period, two-sequence, two-way crossover bioequivalence study of (cytarabine: daunorubicin) liposome for injection manufactured by CSPC Zhongnuo Pharmaceutical Technology Co., Ltd compared with Vyxeos manufactured by Jazz Pharmaceuticals, Inc. in elderly AML subjects. Patients who have achieved CR/CRi after induction treatment will be randomized to sequence A (T-R): (cytarabine: daunorubicin) liposome on C1D1 and C1D3/ Vyxeos on C2D1 and C2D3 or sequence B(R-T): Vyxeos on C1D1 and C1D3/ (cytarabine: daunorubicin) liposome on C2D1 and C2D3. Randomization will be in a 1:1 ratio. Forty to sixty subjects will be enrolled to ensure 36 evaluable subjects.

Serial blood samples for determination of liposomal encapsulated cytarabine and liposomal encapsulated daunorubicin plasma concentration for PK analysis will be obtained in each cycle.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: December 2025
• Est. primary completion date: April 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Able to understand the study and voluntarily sign informed consent.

2. Male or female between 55-75 years of age (inclusive).

3. Subjects diagnosed with acute myeloid leukemia according to "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia" who haven't been treated or who have achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after preceding induction therapy.

4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

5. Adequate hematopoietic, renal and liver function.

6. Cardiac function (LVEF) = 50% and QTcF (Fridericia's) for male<450 ms, for female<470 ms at screening.

7. Women of childbearing potential should agree to use contraceptive measures (such as IUD, contraceptive or condom) during the study and within 6 months after the end of the study.

Exclusion Criteria:

1. Subjects who are diagnosed as acute promyelocytic leukemia.

2. Subjects with clinical evidence of active CNS leukemia.

3. Subjects with any other active malignancy expect for those have been cured (basal cell carcinoma, superficial bladder cancer, cervical cancer in situ, carcinoma in situ of breast or prostate cancer with Gleason score <6).

4. For subjects with induction remission who go directly to randomisation, their antitumour drug elution is required prior to the first dose in the consolidation phase for a minimum of 5 half-lives or 4 weeks, whichever is shorter.

5. Subjects with a history of any major surgery or radiation therapy within 4 weeks prior to the first dose.

6. Subjects with active cardiovascular disease within 6 months prior to the first dose.

7. Subjects with severe hemorrhagic disorders or diseases may cause spontaneous bleeding.

8. Subjects with active or history of cerebrovascular disease, such as stroke, cerebral hemorrhage within 6 months prior to the first dose.

9. Subjects with severe pulmonary disease within 2 weeks prior to the first dose.

10. Subjects with active or uncontrolled infection.

11. Subjects with previous cumulative exposure to anthracyclines >302 mg/m^2 daunorubicin (or equivalent drug equivalent dose level).

12. Subjects with hypersensitivity to liposomal products.

13. Subjects with a history of Wilson's disease or other copper-metabolism disorder.

14. Subjects with known HIV, hepatitis B or hepatitis C infection.

15. Participation in another clinical trial or treatment with any investigational drug within 28 days of study start

16. Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant during the study.

17. Any subject whom the Investigator believes will not be a good candidate for the study.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia

Intervention

Drug:
• (cytarabine: daunorubicin) liposome for injection
Be given intravenously at 65U/m^2 on days 1 and day3 of the first cycle of induction.
• Vyxeos
Be given intravenously at 65U/m^2 on days 1 and day3 of the first cycle of induction.
• (cytarabine: daunorubicin) liposome for injection
Be given intravenously at 65U/m^2 on days 1 and day3 of the second cycle of induction.
• Vyxeos
Be given intravenously at 65U/m^2 on days 1 and day3 of the second cycle of induction.

Locations

Country	Name	City	State
China	Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum (peak) plasma drug concentration (Cmax) of daunorubicin cytarabine liposomes	Maximum (peak) plasma drug concentration is a Pharmacokinetic parameter	30 minutes before administration and 1.5, 2, 5,9,24,48,72,120,168hours after administration of Day 1.
Primary	Area under the plasma concentration versus time curve calculated from 0 to 48h post administration (AUC0-48h) of daunorubicin cytarabine liposomes	Area under the plasma concentration-time curve from time zero to time 48 hours is a Pharmacokinetic parameter	30 minutes before administration and 1.5, 2, 5,9,24,48,72,120,168hours after administration of Day 1
Secondary	Maximum (peak) plasma drug concentration (Cmax) of free daunorubicin and cytarabine	Maximum (peak) plasma drug concentration is a Pharmacokinetic parameter	30 minutes before administration and 1.5, 2, 5,9,24,48,72,120,168hours after administration of Day 1.
Secondary	Area under the plasma concentration versus time curve calculated from 0 to 48h post administration (AUC0-48h) of free daunorubicin and cytarabine	Area under the plasma concentration-time curve from time zero to time 48 hours is a Pharmacokinetic parameterencapsulated and toal cytarabine and daunorubicin after Day 3 treatment of each period.	30 minutes before administration and 1.5, 2, 5,9,24,48,72,120,168hours after administration of Day 1.
Secondary	Maximum (peak) plasma drug concentration (Cmax) of total daunorubicin and cytarabine	Maximum (peak) plasma drug concentration is a Pharmacokinetic parameter	30 minutes before administration and 1.5, 2, 5,9,24,48,72,120,168hours after administration of Day 1.
Secondary	Area under the plasma concentration versus time curve calculated from 0 to 48h post administration (AUC0-48h) of total daunorubicin and cytarabine	Area under the plasma concentration-time curve from time zero to time 48 hours is a Pharmacokinetic parameterencapsulated and toal cytarabine and daunorubicin after Day 3 treatment of each period.	30 minutes before administration and 1.5, 2, 5,9,24,48,72,120,168hours after administration of Day 1.
Secondary	Incidence of treatment-emergent adverse events (TEAEs)		Up to 35 calendar days after the last administration of the investigational product.
Secondary	Complete remission rate	Proportion of subjects with complete remission	Up to 1 year.
Secondary	Composite remission rate	Proportion of subjects with complete response (CR) or complete response with incomplete count recovery (CRi)	Up to 1 year.
Secondary	Relapse-free survival	From the date of remission to the date of relapse after CR/CRi, or death, whichever occurs first.	Up to 3 years.
Secondary	Proportion of subjects who achieve complete remission with MRD negativity		Up to 1 year.